Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

86%

6 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

4(66.7%)

Phase 3

2(33.3%)

6Total

Phase 4(4)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01763411Unknown

Visual Performance of Pseudophakic Patient With Different Intraocular Lenses

Role: lead

NCT02089698Phase 4Completed

Parameters of 2 Phaco Tips Designs in Torsional Phacoemulsification

Role: lead

NCT02084576Phase 4Completed

Anti-inflammatory Efficacy for Prophylaxis of Cystoid Macular Edema (CME) After Phacoemulsification

Role: lead

NCT01505816Phase 4Completed

Visual Outcomes After Implantation of a New Multifocal Intraocular Lens

Role: lead

NCT01065064Phase 4Completed

Visual Performance After RESTOR Implantation

Role: lead

NCT00887900Phase 3Completed

Deep Anterior Lamellar Keratoplasty (DALK)

Role: lead

NCT00870597Phase 3Completed

Transconjunctival Sutureless 25-Gauge Vitrectomy

Role: lead

All 7 trials loaded